Cox pathway

Reading File

The COX (cyclooxygenase) pathway is the enzymatic route by which arachidonic acid is converted into prostaglandins, thromboxanes, and prostacyclin. COX-1 is constitutively expressed; COX-2 is inducible by inflammation. NSAIDs and aspirin act here.

Searching sources...

Finding Sources

Reading File

Loading Image

Reading File

Here is a thorough breakdown of the COX (cyclooxygenase) pathway, compiled from Firestein & Kelley's Textbook of Rheumatology, Lippincott's Pharmacology, and Basic Medical Biochemistry.

The Cyclooxygenase (COX) Pathway

Overview

The COX pathway is one arm of the eicosanoid biosynthesis cascade. It converts arachidonic acid (AA) - a 20-carbon polyunsaturated fatty acid - into prostanoids: prostaglandins (PGs), thromboxanes (TXs), and prostacyclin (PGI2). These lipid mediators regulate inflammation, vascular tone, platelet aggregation, renal function, and many other physiologic processes.

Step 1 - Release of Arachidonic Acid

Arachidonic acid is stored esterified in membrane phospholipids. The first step is its liberation by phospholipase A2 (PLA2) - triggered by mechanical, chemical, or inflammatory stimuli.

Glucocorticoids inhibit PLA2 (by inducing lipocortin/annexin A1), which is one mechanism behind their broad anti-inflammatory effect.

Step 2 - The COX Enzyme (PGHS)

The key enzyme is prostaglandin G/H synthase (PGHS), a bifunctional homodimeric enzyme with two catalytic activities:

Cyclooxygenase (COX) activity - oxygenates arachidonic acid
Peroxidase activity - reduces the initial product

There are two isoforms:

Feature	COX-1 (PGHS-1)	COX-2 (PGHS-2)
Expression	Constitutive (always present)	Inducible
Gene	PTGS1	PTGS2
Location	Platelets, endothelium, gastric mucosa, renal tubules, seminal vesicles	Macrophages, synoviocytes, endothelium, brain, kidney (macula densa)
Function	Homeostatic - gastric protection, platelet TXA2, renal blood flow	Inflammatory - prostaglandins at sites of injury/chronic disease
Induced by	Constitutive (Sp1 transcription factor)	IL-1β, TNF-α, NF-κB, AP-1; also oxidative stress, ischemia, seizures
Inhibited by	NSAIDs (non-selective)	NSAIDs, glucocorticoids, selective COX-2 inhibitors (coxibs)
Active site	Narrower hydrophobic channel	Slightly larger channel (allows selective inhibitor entry)

COX-2 mRNA also contains ~12 AUUUA instability motifs, making the transcript short-lived and its expression tightly controlled.

Step 3 - Biosynthetic Reactions

COX pathway: arachidonic acid to prostanoids

Fig. Cyclooxygenase pathway from arachidonic acid to PGH2 and downstream prostanoids (Firestein & Kelley's Rheumatology)

Reaction 1 - COX activity: AA → PGG2

Cyclooxygenase activity inserts 2 O2 molecules across carbons 9 and 11, and at carbon 15
Ring closure occurs between C8 and C12, creating the five-membered cyclopentane ring
Product: PGG2 (an unstable bicyclic endoperoxide with a hydroperoxy group at C15)
Requires double bonds at C8, C11, and C14 in the precursor fatty acid

Reaction 2 - Peroxidase activity: PGG2 → PGH2

The hydroperoxy group (-OOH) at C15 is reduced to a hydroxyl group (-OH) by the peroxidase activity of the same enzyme
Glutathione (GSH) serves as the reducing agent
Product: PGH2 (prostaglandin H2) - the key branch-point intermediate

Step 4 - Tissue-Specific Downstream Products from PGH2

PGH2 is acted on by terminal synthases that vary by cell type:

Terminal Synthase	Product	Primary Source	Key Actions
Thromboxane synthase	TXA2	Platelets	Potent vasoconstrictor; platelet aggregation; promotes thrombosis
Prostacyclin synthase	PGI2 (prostacyclin)	Vascular endothelium	Vasodilator; inhibits platelet aggregation (opposes TXA2)
PGE synthase	PGE2	Macrophages, fibroblasts	Vasodilation, fever, pain sensitization, inhibits gastric acid
PGD synthase	PGD2	Mast cells, brain	Bronchoconstriction, sleep induction, allergy
Endoperoxide reductase / PGE 9-ketoreductase	PGF2α	Uterus, lung	Uterine contraction, bronchoconstriction

TXA2 is chemically unstable (half-life ~30 sec) and hydrolyses spontaneously to inactive TXB2. PGI2 also has a short half-life (~2 min) and converts to 6-keto-PGF1α.

Prostaglandin Nomenclature

Ring substituents of prostaglandins PGA, PGD, PGE, PGF, PGG/H, PGI

Fig. Ring substituents of the prostaglandin series (Basic Medical Biochemistry)

Letter (PGE, PGF, etc.) = configuration of the ring substituents
Subscript number (PGE2) = number of double bonds in the linear chain (series 2 comes from arachidonic acid, the most common in humans)
Greek letter (PGF2α) = orientation of the C9 hydroxyl (only in F series)

COX Pathway Gene Regulation

Fig. Regulation of COX-1 and COX-2 synthesis (Lippincott's Pharmacology)

COX-1: constitutive expression via the Sp1 transcription factor; TATA-less promoter; cannot be readily induced or silenced
COX-2: key transcriptional elements include NF-κB and the AP-1/cAMP response element; activated by inflammatory cytokines (IL-1β, TNF-α), oxidative stress, ischemia, and growth factors; suppressed by glucocorticoids

Pharmacological Targets in the COX Pathway

Drug Class	Mechanism	Example Drugs
Non-selective NSAIDs	Block both COX-1 and COX-2 by occluding the active-site hydrophobic channel	Ibuprofen, naproxen, indomethacin
Aspirin	Irreversible acetylation of COX-1 (and COX-2 at higher doses) at Ser530; particularly prevents TXA2 in platelets	Aspirin
Selective COX-2 inhibitors (coxibs)	Fit into the larger COX-2 active site; spare COX-1 (gastric protection)	Celecoxib, etoricoxib
Glucocorticoids	Inhibit PLA2 (reduce AA release) + suppress COX-2 gene transcription	Dexamethasone, prednisolone

Aspirin's irreversible block is especially important in platelets because platelets are anucleate - they cannot regenerate COX-1. So even low-dose aspirin (~81 mg) provides long-lasting antiplatelet effect for the 7-10 day platelet lifespan.

Physiological Roles of Key Prostanoids

Prostanoid	Vascular	Platelets	Kidney	Uterus	GI tract
TXA2	Vasoconstriction	Aggregation ↑	-	-	-
PGI2	Vasodilation	Aggregation ↓	Renal blood flow ↑	-	-
PGE2	Vasodilation	-	Renin release; Na+ excretion	Contraction	Mucus ↑; acid ↓
PGF2α	Vasoconstriction	-	-	Strong contraction	-
PGD2	Vasodilation	Aggregation ↓	-	-	-

Clinical Relevance

NSAIDs/aspirin - most widely used drugs acting on this pathway; side effects (peptic ulcer, renal impairment) are largely COX-1-mediated
Coxibs - reduced GI risk but increased cardiovascular risk (by sparing PGI2 synthesis in endothelium while not reducing platelet TXA2)
Misoprostol (PGE1 analog) - used to protect gastric mucosa or induce labor
Carboprost / Dinoprostone (PGF2α / PGE2 analogs) - uterotonic agents
Latanoprost (PGF2α analog) - reduces intraocular pressure in glaucoma

Sources:

Firestein & Kelley's Textbook of Rheumatology, Chapter 27, p. 540
Basic Medical Biochemistry - A Clinical Approach, 6e, Chapter 31, pp. 1136-1139
Lippincott Illustrated Reviews: Pharmacology, Chapter 40, pp. 1334-1338

Create a diagram summarizing COX pathway targets and NSAID mechanisms

Generating Image

A detailed medical biochemistry diagram titled "COX Pathway Targets & NSAID Mechanisms" showing: Top: Membrane phospholipids with an arrow pointing down labeled "Phospholipase A2" leading to Arachidonic Acid. A red blocked arrow labeled "Glucocorticoids" blocking Phospholipase A2. Middle section split into two parallel branches: - Left branch: COX-1 enzyme box (labeled "Constitutive - always expressed") with icons for platelets, gastric mucosa, kidney, endothelium - Right branch: COX-2 enzyme box (labeled "Inducible - upregulated by IL-1β, TNF-α, NF-κB") with icons for macrophages, synoviocytes, brain Both COX-1 and COX-2 arrows have red blocked lines: - "Aspirin (irreversible acetylation Ser530)" blocking COX-1 - "NSAIDs (ibuprofen, naproxen)" blocking both COX-1 and COX-2 - "Selective COX-2 inhibitors (celecoxib)" blocking only COX-2 Both branches converge on "PGH2 (common precursor)" in the center Bottom: PGH2 branches into five downstream products with tissue labels and color-coded arrows: 1. TXA2 (Thromboxane A2) - red box - "Platelets: vasoconstriction, platelet aggregation → thrombosis" 2. PGI2 (Prostacyclin) - green box - "Endothelium: vasodilation, inhibits platelet aggregation" 3. PGE2 - orange box - "Macrophages: fever, pain, inflammation, gastric protection" 4. PGD2 - purple box - "Mast cells: bronchoconstriction, allergy" 5. PGF2α - blue box - "Uterus: smooth muscle contraction" Bottom annotation box: "Clinical Note: Aspirin spares platelets (anucleate, cannot regenerate COX-1) → antiplatelet effect lasts 7-10 days. COX-2 inhibitors spare GI mucosa but increase CV risk by shifting TXA2/PGI2 balance" Clean white background, professional medical illustration style, color-coded pathways, clear legible labels, bold arrows

Here's a summary of what the diagram covers:

Upstream inhibition:

Glucocorticoids block Phospholipase A2 - preventing arachidonic acid release entirely

COX enzyme level:

Aspirin - irreversibly acetylates Ser530, blocking both COX-1 and COX-2; uniquely effective in platelets because they cannot regenerate the enzyme
Non-selective NSAIDs (ibuprofen, naproxen, diclofenac) - reversibly block both isoforms
Selective COX-2 inhibitors (celecoxib, etoricoxib) - fit only into the slightly larger COX-2 active site; spare COX-1

Downstream products from PGH2:

Product	Source	Effect
TXA2	Platelets	Vasoconstriction, aggregation
PGI2	Endothelium	Vasodilation, anti-aggregation
PGE2	Macrophages	Fever, pain, inflammation
PGD2	Mast cells	Bronchoconstriction
PGF2α	Uterus	Smooth muscle contraction

Key clinical takeaway: COX-2 inhibitors reduce GI side effects (by sparing COX-1-driven gastric protection) but increase cardiovascular risk - they suppress endothelial PGI2 without reducing platelet TXA2, tipping the balance toward thrombosis.

This is a shared conversation. Sign in to Orris to start your own chat.